Sovateltide
Pharmazz, Inc, a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, announced the initiation of dosing in its pivotal, phase 3 clinical trial evaluating sovateltide for the treatment of acute cerebral ischemic stroke